LIquid Biopsy to prEdict Responses To First-line immunotherapY in Metastatic Non-small Cell LUNG Cancer. LIBERTY LUNG

Launched by INSTITUT CURIE · Mar 5, 2021

Keywords

ClinConnect Summary

The LIBERTY LUNG trial is researching how a special blood test, called a liquid biopsy, can help predict how well patients with metastatic non-small cell lung cancer (NSCLC) will respond to initial treatment with immune therapy. This trial is specifically looking for adults aged 18 and older who have been diagnosed with advanced NSCLC and have not yet received any treatment. To qualify, participants need to have measurable cancer based on imaging tests and must not have certain genetic mutations related to their cancer.

If you join this study, you can expect to provide a sample of your tumor tissue for testing and undergo a blood test to monitor specific cancer markers over time. The study is currently recruiting participants and is open to anyone who meets the eligibility criteria, including those who may be receiving other treatments that do not interfere with the study. Importantly, all participants will need to give their consent to take part in the trial. This research could help doctors better understand how to tailor treatments for patients with metastatic lung cancer in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Histologically-proven NSCLC.
• • 2. Age ≥ 18 years.
• • 3. Advanced or metastatic stage IV.
• • 4. Treatment-naïve patient.
• • 5. Eligibility to first-line treatment with immune checkpoint inhibitor.
• • 6. Measurable disease according to RECIST 1.1 criteria on CT-Scan.
• • 7. Availability of expression of PD-L1 at immunohistochemistry analysis of the tumor biopsy.
• • 8. No ALK or EGFR gene alteration.
• • 9. Availability of tumor tissue for NGS analysis (7 slides).
• • 10. PS 0 or 1.
• • 11. Signed informed consent of the patient.
• Exclusion Criteria:
• • 1. No social security affiliation.
• • 2. Person under legal protection.
• • 3. Pregnant and breastfeeding women.
• • Patients can participate to another clinical trial that is not modifying immunotherapy or immunotherapy/chemotherapy treatment nor study follow-up ; after investigator's information